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Abstract 
A number of commentaries have been published over the past 4 years by the present author on the manifest flaws in the reference 
case value assessment framework of the Institute for Economic and Clinical Review. The recent release of the evidence report on sickle 
cell disease continues ICER’s commitment to what has been described as the creation of imaginary worlds to support value assessment. 
The purpose of the present commentary is to continue the critiques that have been presented for earlier evidence reports. This is 
important because of the apparent willingness to take ICER’s recommendations at face value rather than a critical review of the value 
assessment framework. The case presented here points to a  number of weaknesses in the ICER framework: (i) the fabrication of 
imaginary constructs with a lifetime cost-per-incremental QALY framework; (ii) the consequent failure to meet the standards of normal 
science; (iii) the illogical reliance of assumptions drawn from the literature to create future scenarios; (iv) the rejection of hypothesis 
testing in favor of  ‘approximate information’ and (v) a belief that in the construction of QALYS that the EQ-5D-3L utility scale has ratio 
properties. This last point is demonstrably false which means that the ICER value assessment framework collapses. It is impossible 
mathematically, a failure to meet the axioms of fundamental measurement, for an ordinal utility scale to be combined with time spent 
in a disease state. The result is that the pricing and access recommendations for Crizanlizumab, Voxelotor and L-glutamine in sickle cell 
disease (SCD) are complete nonsense and should be rejected. 
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Introduction 
 
Insinuate: to introduce by stealthy, smooth, or artful means 
(Merriam Webster) 
 
Over the past few years the Institute for Clinical and Economic 
Review (ICER) has attempted to insinuate itself as the principal 
arbiter for value assessments in the US. The ICER business 
model is built around the construction of lifetime imaginary 
simulations which claim to provide a framework relevant to 
health system decision makers for pricing and access with 
pharmaceutical products and devices. As detailed in a recent 
review of the ICER value assessment framework, the ICER 
modeling approach fails to meet the standards of normal 
science; the discovery of new facts 1. It is best characterized as 
pseudoscience (i.e., bunk). Constructing imaginary worlds to 
support pricing and access recommendations has certainly 
characterized health technology assessment of the past  
30 plus years. Indeed, the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) makes 
clear that it is not interested in hypothesis testing or the  
discovery of new facts in treatment impact 2. ISPOR sees its 
principal role in generating ‘approximate information’ in  
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contrast to real world evidence where meaningful claims for 
therapy impact and quality of life in disease areas can be 
evaluated from patient-centric evidence platforms.  
 
The purpose of the present commentary is to point to the 
manifest flaws in the latest attempt by ICER to fabricate 
imaginary recommendations for pricing and access 3. This is a 
critical issue as ICER recommendations can ensure that the 
access to new therapies, in this case for sickle cell disease, is 
barred to those most in need. ICER has the responsibility for 
defending its position; not only for pricing recommendations 
but for denying access to new therapies. Unfortunately, 
irrespective of ICERs claim that it adheres to ‘gold standard’ 
techniques in its fabrication of imaginary cost-per-QALY 
worlds to support its revelations, its methodology is fatally 
flawed. Yet ICER perseveres in a program of making 
recommendations for price discounting and access on a value 
assessment framework that defy the standards of normal 
science. 
 
What needs to be made clear is the absurdity of the ICER value 
assessment framework in this latest application in sickle cell 
disease in its final evidence report 4. This stems from (i) the 
fabrication of imaginary constructs with a lifetime cost-per-
incremental QALY framework; (ii) the consequent failure to 
meet the standards of normal science; (iii) the illogical reliance 
of assumptions drawn from the literature to create future 
scenarios; (iv) the rejection of hypothesis testing in favor of 
‘approximate information’ and (v) a belief that in the 
construction of QALYS that the EQ-5D-3L utility scale has ratio 
properties.  
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The Imaginary Worlds of ICER 
 
Imaginary: existing only in the imagination (Oxford 
Dictionaries) 
 
Imaginary worlds can be compelling; from Peter Pan to Harry 
Potter millions of children (and adults) have been enthralled 
with their creativity and their identification with the leading 
characters. Health technology assessment, as understood and 
proselytized by groups such as the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) in their 
advocacy of approximate imaginary information created by 
imaginary lifetime reference case worlds, has been in the 
forefront in advocating practice standards for fantasy creations. 
 
The imaginary simulated world for SCD has as its primary 
objective a decision analytic framework to estimate the lifetime 
cost-effectiveness of three treatments for SCD: crizanlizumab 
(Novartis AG), voxelotor (Global Blood Therapeutics), and L-
glutamine Emmaus), each combined with usual care, compared 
to usual care alone. The model estimates imaginary outcomes 
that include life years gained, quality-adjusted life years 
(QALYs) gained, equal value life years gained (evLYG), clinical 
events, pain crises avoided, change in hemoglobin, and total 
costs for each intervention over a lifetime time horizon. The 
base-case analysis used a health care sector perspective (i.e., 
direct medical care costs only), with the societal perspective as 
a co-base case, presented directly alongside the health care 
sector perspective analysis. 
 
The model is a cohort-level, Markov model of costs, quality of 
life (QoL), clinical events, and mortality associated with SCD 
among children and adults in the US diagnosed with the 
disease, using a 2-week cycle length. This approach was chosen 
due to the chronic nature of disease and the multiple re-
occurring events in SCD. The model focuses on transitions 
between acute and chronic health states and includes the risk 
of death. Treatments that delay or avoid acute and chronic 
conditions will, in the model framework, improve patients’ 
health, quality of life, and health care costs. Evidence of 
treatment effects on acute pain crises and level of hemoglobin 
come directly from the pivotal trials. Evidence linking the 
relationship between acute pain crises and levels of 
hemoglobin to other acute and chronic conditions come from 
multiple sources and assumptions as these were not directly 
measured in the clinical trials. 
 
The intricacies of the SCD model are not of concern here. After 
all, although data are drawn from the various pivotal clinical 
trials, data are also drawn from a variety of other sources to 
create the model assumptions. This model is one of many, if not 
a multiverse of different models, to support imaginary 
competing claims for therapy impacts in SCD. The key point, 
from the perspective of an imaginary construct with lifetime 
non-credible (and obviously non-evaluable) claims is the 
construction of quality adjusted life years, lifetime QALY 
estimates for the various assumed and modeled treatment 
pathways, lifetime costs and, the pièce de résistance, 
incremental cost-per-QALY estimates to support threshold 
analysis and the much awaited ICER recommendations for price 
discounting from WAC. Our focus, therefore, is on the QALY and 
whether the model assumptions regarding how utilities are 
‘discovered’ and assigned and QALYs created make any sense 
from the perspective of normal science. 
 
Although judged here as nonsensical, given the manifest flaws 
in the SCD model in respect of the criteria of normal science and 
the disregard of fundamental measurement theory. ICER 
recommends substantial discounts from wholesale acquisition 
costs (WAC): crizanlizumab 70% to 74%; voxelotor 79% to 83%; 
and L-glutamine 35% to 40%. These should be ignored as they 
fall squarely in the realm of pseudoscience. 
 
The Standards of Normal Science 
 
Pseudoscience: a collection of beliefs or practices mistakenly 
regarded as being based on scientific method (Oxford 
Dictionaries) 
 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for pharmaceutical 
products and devices is unexceptional. Since the 17th century, it 
has been accepted that if a research agenda is to advance, if 
there is to be an accretion of knowledge, there has to be a 
process of discovering new facts. ICER is opposed to this. By the 
1660s, the scientific method, following the seminal contributions 
of Bacon, Galileo, Huygens and Boyle, had been clearly 
articulated by associations such as the Academia del Cimento in 
Florence (1657) and the Royal Society in England (founded 1660; 
Royal Charter 1662) with their respective mottos Provando e 
Riprovando (prove and again prove) and nullius in verba (take no 
man’s word for it) 5.  
By the early 20th century, standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 6 7 .  Hypotheses or claims must be capable of 
falsification; indeed, they should be framed in such a way that 
makes falsification likely. Although Popper’s view on what 
demarcates science (e.g., natural selection) from pseudoscience 
(e.g., intelligent design) is now seen as an oversimplification 
involving more than just the criteria of falsification, the 
demarcation problem remains 8.  Certainly, there are different 
ways of doing science but what all scientific inquiry has in 
common is the ‘construction of empirically verifiable theories 
and hypotheses’. Empirical testability is the ‘one major 
characteristic distinguishing science from pseudoscience’; 
theories must be tested against data. Hence pivotal clinical trials; 
not simulated imaginary worlds with selected data inputs from 
pivotal trial data to recycle old (and imagined) facts. We can only 
justify our preference for a theory by continued evaluation and 
replication of claims. This applies in SCD just as it does in other 
therapies. Constructing imaginary worlds, even if the 
justification is that they are ‘for information’ is, to use Bentham’s 
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(Jeremy Bentham 1748-1832) memorable phrase ’nonsense on 
stilts’. If there is a belief, as subscribed to by ICER, in the sure and 
certain hope of constructing imaginary worlds, to drive 
formulary and pricing decisions, then it needs to be made clear 
that this is a belief that lacks scientific merit. It fails the 
demarcation test; it is pseudoscience (i.e., pure bunk).  
Approximate Information (or Disinformation) 
Approximate: close to the actual, but not completely accurate 
or exact (Oxford Dictionaries) 
It is worth emphasizing that ISPOR, as noted above, ICER’s 
methodological mentor, explicitly disavows hypothesis testing as 
a core activity in health technology assessment. The primary role 
of health technology assessment is to create ‘approximate 
information’. It is not clear what this means (presumably it can 
be distinguished from ‘approximate disinformation’) as there is 
not, in the imaginary world of ICER modeling, any known 
reference point for ‘true information’ to judge approximation. 
How close are we? It is difficult to be approximate to the ‘truth’ 
when the context is imaginary and the ‘truth’ will only be 
revealed 10, 20 or 30 years or more ahead if all the assumptions 
in the model are realized. The OED definition may relate 
approximate to a ‘known’ truth but in the construction of 
imaginary worlds then can be no such reference point. 
Choice of Assumptions 
 
Assumptions: a thing that is accepted as true or as certain to 
happen, without proof (Oxford Dictionaries) 
 
The ICER claim to fame is the ability to construct or fabricate an 
imaginary world that sets the stage for value impact over 10, 20 
or 30 years in the future. In the SCD model the number of 
assumptions made to support the various simulations and their 
scenario progeny across the three therapies is truly awesome; 
some come from the literature, others are pure guesswork. 
Unfortunately, even if an assumption driving the imaginary 
value assessment framework is defended by appealing to the 
literature (including pivotal clinical trials) the effort is wasted. 
The point, and this goes back to Hume’s (David Hume 1711 – 
1776) induction problem, is that we cannot ask clients in health 
care to believe in models constructed on the belief that prior 
assumptions will hold into the future. It is logically indefensible: 
it cannot be ‘established by logical argument, since from the 
fact that all past futures have resembled past pasts, it does not 
follow that all future futures will resemble future pasts’ 9. No, 
Virginia, all swans are not white. You may have seen only 
English swans, but on my last QANTAS vacation in Western 
Australia, I saw black swans.  
 
Achilles, Utilities and QALYs 
 
Achilles Heel:  a weakness or vulnerable point (Oxford 
Dictionaries) 
 
QALYS are the Achilles heel of the ICER construction and belief 
in imaginary reference case lifetime worlds; exeunt QALYs and 
the fantasy edifice collapses.  Apart from their use in the ICER 
contribution to the science fiction literature, QALYs can only 
survive if the measure is credible, evaluable and replicable. The 
QALY constructed by ICER in the SCD model meets none of 
these criteria. In fact, there is only one reference cited in SCD in 
the ICER report for utilities, in this case the EQ-5D-3L, self-
assessment in a hospital environment, the balance of utilities 
are for other, possibly similar, disease states 10. The concept of 
a QALY is not new; it goes back some 40 plus years with the 
notion of combining time spent in a disease state with some 
multiplicative ‘score’ on a  required interval scale of 0 to 1 
(death to perfect health).  Combining the two, multiplying time 
by utility is assumed to produce a QALY. In the ICER imaginary 
SCD world these are combined to produce QALYs for the 
modeled lifetime. However, before considering the EQ-5D-3L 
utility that is central to the imaginary SCD simulation, a brief 
digression on measurement theory and its application to 
instrument development in the social science is on order.  
 
There are four main types of measurement scale; putting to one 
side conjoint simultaneous measurement which underpins 
Rasch Measurement Theory (RMT)11.  These are: nominal, 
ordinal, interval and ratio. Each satisfies one or more of the 
properties of: (i) identity, where each value has a unique 
meaning; (ii) magnitude, where each value has an ordered 
relationship to other values; (iii) interval, where scale units are 
equal to one another; and (iv) ratio, where there is  a ‘true zero’ 
below which no value exists. Nominal scales are purely 
descriptive and have no inherent value in terms of magnitude. 
Ordinal scales have both identity and magnitude in an ordered 
relation but the unknown distances between the ranks means 
the scale is capable only of generating median and modes. The 
interval scale has identity, magnitude and equal intervals. It 
supports mathematical operations of addition and subtraction. 
A ratio scale satisfies all properties, supporting the additional 
mathematical operations of multiplication and division. 
Recognition and adherence to these fundamental axioms of 
measurement theory is critical if a measure is t have any 
credibility. In the physical sciences this has been long 
recognized as accurate measurement is key to hypothesis 
testing and the discovery of new facts. The same arguments 
apply to the social sciences. Unfortunately, they appear all too 
often absent in health technology assessment. 
 
The case presented here is that the EQ-5D-3L generates ordinal 
or manifest scores12. It does not have interval properties (i.e., 
invariance of comparisons) and it certainly does not have ratio 
properties as the EQ-5D-3L ‘score’ lacks a true zero i.e., distance 
from zero). Unfortunately, the EQ-5D-3L scale has no 
demonstrable interval measurement properties (with odd 
ceiling and floor effects) as well allowing negative utilities 
(below a true zero). Of course, if the EQ-5D-3L fails to 
demonstrate interval properties, then it is a waste of time to 
consider whether it has ratio properties. The actual range for 
the EQ-5D-3L is not from 0 = death to 1 = perfect health, but 
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from -0.59 to 1.0 as the algorithm to compute utilities allows 
negative values. The fact that the EQ-5D-3L has ordinal 
properties is easily demonstrated: the symptom elements that 
comprise the EQ-5D-3L attributes are on an ordinal scale. 
Simply applying community preference weights results in a 
composite ordinal scale. 
 
There is the further question of unidimensionality. 
Measurement scales should have the property of 
unidimensionality. The focus should be on one attribute at a 
time.   We must avoid confusing a number of attributes into a 
single score. Mutiattribute scales such as the EQ-5D-3L reduce 
confidence in predictions and the score is a less useful summary. 
In Rasch modeling, estimates of item difficulty and person ability 
are meaningful if every question contributes to the 
measurement of a single underlying attribute. Our analytical 
procedures, if we are to meet the property of unidimensionality, 
must incorporate indicators of the extent to which the persons 
and items fit our concept of an ideal unidimensional line. Items 
should contribute in a meaningful way to the construct/concept 
being investigated. 
 
In the case of the EQ-5D-3L the notion of unidimensionality is 
absent. While it is claimed to capture health related quality of 
life (HRQoL), there is no single attribute or latent construct. It 
comprises 5 symptoms (mobility, self-care, usual activity, 
pain/discomfort, anxiety depression) with three ordinal 
response levels (no problem, some problems and major 
problems); creating a multiattribute scale with ordinal 
properties. Each of the symptoms is an attribute that could be 
the foundation for its own unidimensional scale. While ICER 
apparently believes the EQ-5D-3L has ratio properties this is  
demonstrably false given negative utilities. But perhaps this is 
not as egregious as the ‘false assumption’ position taken by 
authors where it is acknowledged that the EQ-5D-3L lacks a true 
zero but that, in order to maintain the QALY illusion, we assume 
it has ratio properties 13:  
 
The situation does not change when we move from the EQ-5D-
3L to the EQ-5D-5L (introduced in 2009) where there are 5 
response levels. Increasing the allowed ordinal responses to five 
reduces the number of respondents with extreme problems. The 
result is a range, still including negative utilities, from -0.29 to 
1.0. Even so, it is still an ordinal or manifest score. 
 
Even if ICER were willing to recognize the absence of 
fundamental measurement properties in the EQ-5D-3L (and 
other generic utility instruments), this does not mean that this 
would give succor to the belief in fabricated imaginary 
evidence. The ICER value assessment framework would still fail 
the demarcation test as pseudoscience.  It is also difficult to see 
how ICER might underwrite a ‘utility’ instrument that met the 
standards required (a true zero yet capped at unity). After all, 
instruments developed by application of RMT focus on the 
response to interventions on a constructed interval scale from 
ordinal responses rather than attempting to go the further step 
of creating instruments which have ratio properties  14 15 16.  
Conclusion: Next Steps 
 
The fact that the application of utility values, from a variety of 
sources to create QALYS, fails the standards of fundamental 
measurement should be sufficient to show that the ICER 
reference case model for SCD (and all previous evidence based 
disease claims) should be rejected; unfortunately, this will not 
deter ICER. The company has too much invested in its claim as 
the US technology assessment arbiter of emerging products 
and technologies. After all, it would be embarrassing to admit 
that its recommendations for pricing and access are, to say the 
least, nonsensical, and that the ICER value assessment 
framework is more appropriately classified with intelligent 
design than natural selection.  
 
In SCD, it will be up to the manufacturers to make the case for 
ignoring ICER to health system decision makers. They will have 
to offer an alternative approach to evaluating the ‘value’ of 
their products. Previous commentaries have proposed that 
rather than focusing on generic utilities and QALYs, 
manufacturers should direct their activities to claims based on 
disease specific QoL instruments. Since the mid-1990s disease 
specific (both patient and caregiver) instruments have been 
developed with needs fulfillment as the latent unidimensional 
construct. The instruments meet the required standards of RMT 
to create an instrument with interval measurement properties 
to assess response to therapy: does a new therapy contribute 
to patients needs being more effectively met in a disease state? 
An instrument that meets these standards should be 
considered in SCD. Developing such an instrument would 
provide a complement to the Adult Sickle Cell Quality of Life 
Measurement Information System (ASQ-Me) 17. While the ASQ-
Me is not patient centric, as it lacks a focus on needs fulfilment 
(it also does not meet RMT standards), there are elements from 
this system that should be retained (e.g., evaluation of pain 
experience).  
 
Adopting a disease specific, RMT standard patient centric 
instrument, or rather a family of instruments that capture 
pediatric patients, their caregivers and adults with SCD, gives a 
sound basis for evaluating response to therapy. It would 
provide claims that are credible, evaluable and replicable. It 
would be a simple index of response to therapy and could be an 
integral part of evidence platforms such as registries in SCD. The 
fact is, we don’t need ICER (or any other group) to spend eight 
months from conception through gestation to produce an 
imaginary construct that fails the standards of normal science. 
A commitment to fantasy creations that is, surprisingly, 
supported financially by manufacturers; they should know 
better. A return to the standards of normal science, to the 
discovery of new facts in the treatment and response to 
therapies in diseases such as SCD would be a welcome respite 
from, and antidote to, ICER. 
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